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Abstract
Background: The rate of gastric emptying and glucoregulatory hormones are key determinants of postprandial
glycaemia. Intragastric administration of L-tryptophan slows gastric emptying and reduces the glycaemic response to
a nutrient drink in lean individuals and those with obesity. We investigated whether tryptophan decreases
postprandial glycaemia and slows gastric emptying in type 2 diabetes (T2D).
Methods: Twelve men with T2D (age: 63 ± 2 years, HbA1c: 49.7 ± 2.5 mmol/mol, BMI: 30 ± 1 kg/m2) received, on three
separate occasions, 3 g (‘Trp-3’) or 1.5 g (‘Trp-1.5’) tryptophan, or control (0.9% saline), intragastrically, in randomised,
double-blind fashion, 30 min before a mixed-nutrient drink (500 kcal, 74 g carbohydrates), containing 3 g 3-O-methyl-
D-glucose (3-OMG) to assess glucose absorption. Venous blood samples were obtained at baseline, after tryptophan,
and for 2 h post-drink for measurements of plasma glucose, C-peptide, glucagon and 3-OMG. Gastric emptying of the
drink was quantified using two-dimensional ultrasound.
Results: Tryptophan alone stimulated C-peptide (P= 0.002) and glucagon (P= 0.04), but did not affect fasting
glucose. In response to the drink, Trp-3 lowered plasma glucose from t= 15–30 min and from t= 30–45 min
compared with control and Trp-1.5, respectively (both P < 0.05), with no differences in peak glucose between
treatments. Gastric emptying tended to be slower after Trp-3, but not Trp-1.5, than control (P= 0.06). Plasma C-
peptide, glucagon and 3-OMG increased on all days, with no major differences between treatments.
Conclusions: In people with T2D, intragastric administration of 3 g tryptophan modestly slows gastric emptying,
associated with a delayed rise, but not an overall lowering of, postprandial glucose.
Introduction
Gastric emptying and the release of the glucoregulatory
hormones, insulin and glucagon, are important determi-
nants of the postprandial blood glucose response to
carbohydrate-containing meals, in health, obesity and
type 2 diabetes (T2D)1. For example, gastric emptying,
which exhibits a substantial inter-individual variation,
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accounts for about 35% of the variance in peak post-
prandial blood glucose1. Slowing of gastric emptying, by
dietary or pharmacological means, attenuates post-
prandial glycaemic excursions, particularly during the first
30–60 min postprandially2,3. Gastric emptying and the
release of glucoregulatory hormones can be influenced by
nutrients4,5. For example, in T2D, whey protein, when
given as a preload 30 min before a high-carbohydrate
meal, slowed gastric emptying and stimulated insulin,
leading to a reduction in the glycaemic response6. These
effects of protein appear to be mediated, at least in part,
by their digestion products, amino acids — both circu-
lating amino acids and as a result of the interaction of
amino acids with the small intestine7–10.
A number of amino acids have been shown to reduce
the blood glucose response to glucose or mixed-nutrient
drinks11–15. The aromatic amino acid, tryptophan, is of
particular interest; it potently stimulates pyloric motility
and plasma cholecystokinin (CCK) concentrations, which
are both central to the slowing of gastric emptying16,17.
Solutions containing tryptophan, when administered
intragastrically or orally, empty from the stomach more
slowly than control solutions18,19. We reported that
intragastric administration of 3 g tryptophan slowed gas-
tric emptying of a mixed-nutrient drink, consumed
15min later, associated with a reduced glycaemic
response in the first 30 min, in both lean individuals and
those with obesity who do not have T2D15. That intra-
gastric tryptophan had a minimal16, or no19, effect to
stimulate insulin, and may reduce insulin15, suggests that
the attenuation in postprandial blood glucose is unlikely
to reflect an insulinotropic effect of tryptophan. Like other
amino acids, tryptophan has been reported to stimulate
glucagon15,16, which may potentially counteract glucose
lowering by stimulating glycogenolysis and gluconeogen-
esis. Hence, slowing of gastric emptying is likely to be
fundamental to a reduction in postprandial glycaemia by
tryptophan. The above considerations are of relevance to
the management of T2D; it is now appreciated that
postprandial glycaemic excursions are a major determi-
nant of overall glycaemic control, as assessed by mea-
surement of glycated haemoglobin, and the consequent
risk of microvascular complications (i.e. retinopathy,
nephropathy and neuropathy). However, there is no
information about the effects of tryptophan in T2D. The
observed reduction in postprandial glucose resulting from
slowing of gastric emptying, induced by tryptophan,
should intuitively be associated with a reduction in the
rate of carbohydrate absorption, as supported by animal
studies20. Glucose absorption can be measured in humans
using plasma concentrations of the non-metabolisable
glucose analogue, 3-orthomethyl-glucose (3-OMG)21.
The aim of the current study was to evaluate the effects
of intragastric administration (to avoid potential
confounding effects of taste) of tryptophan on the gly-
caemic response to, as well as glucoregulatory hormones
and glucose absorption, and gastric emptying of, a mixed-
nutrient drink in people with T2D.
Materials and methods
Participants
Twelve men with T2D (mean age: 63 ± 2 years, BMI:
30 ± 1 kg/m2, HbA1c: 49.7 ± 2.5 mmol/mol (6.7 ± 0.1%),
duration of diabetes: 10 ± 2 years) participated in the
study. Their diabetes was managed by metformin
(500–2000 mg/day) alone (n= 7), or in combination
with a DPP-4 inhibitor (n= 2) or a sodium-glucose
transport inhibitor (n= 3). Participants were recruited
by flyers placed at the Royal Adelaide Hospital and
Diabetes South Australia, and through advertisements
on online sites (University of Adelaide and Gumtree).
Participants were excluded if they had significant gas-
trointestinal disorders or symptoms, cardiovascular or
respiratory diseases or surgery, used medication known
to affect gastrointestinal function and/or appetite, were
lactose-intolerant, consumed protein supplements or
>2 standard drinks (20 g) alcohol on >5 days a week,
were vegetarians or smokers, or had an estimated glo-
merular filtration rate <45 mL/min, or low serum ferri-
tin (<30 μg/L) or iron (<8 μmol/L) levels (a requirement
by the Human Research Ethics Committee). In all cases,
autonomic nerve function was evaluated using stan-
dardised cardiovascular reflex tests, and the presence of
autonomic neuropathy (i.e. a score ≥3) represented an
exclusion22. After inclusion, each participant was allo-
cated to a treatment order of balanced randomisation
(www.randomization.com) by a research officer who was
not involved in data analysis. The Human Research
Ethics Committee of the Central Adelaide Local Health
Network approved the study protocol, and the study was
performed in accordance with the Declaration of Hel-
sinki and the National Health and Medical Research
Council of Australia Statement on Ethical Conduct in
Human Research. All participants provided written
informed consent before inclusion. The study was
registered as a clinical trial with the Australia and New
Zealand Clinical Trials Registry (www.anzctr.org.au)
(trial number: ACTRN12613000899741).
Study design
We investigated the effects of intragastric adminis-
tration of (i) 3 g (Trp-3) or (ii) 1.5 g (Trp-1.5) trypto-
phan, or (iii) control (0.9% saline) on plasma glucose
(the primary outcome), C-peptide (a measure of insulin
secretion), and glucagon concentrations and glucose
absorption in response to, and gastric emptying of, a
mixed-nutrient drink, consumed 30 min after the
intragastric treatments.
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Control and tryptophan treatments
Tryptophan treatments were prepared by dissolving
1.5 g or 3 g food-grade tryptophan (PureBulk Inc., Rose-
burg, Oregon, USA), 58 mg CaCl2xH2O, and 1.75 g or
1.65 g NaCl, respectively, in 200-mL water for irrigation.
Control solutions consisted of 58 mg CaCl2xH2O and
1.85 g NaCl in 200-mL water. The solutions were
approximately iso-osmolar (control: 296, 1.5 g: 318, 3 g:
335mOsm/kg) and had a pH of ~7 and a temperature of
~23 °C. Solutions were prepared by a research officer, who
was not involved in the performance of the studies or data
analysis, on the morning of each study and administered
via a nasogastric catheter directly into the stomach. Syr-
inges were covered, so that both study participants and
the investigators performing the study were blinded to the
nature of the solution. The doses of tryptophan were
chosen based on our previous work and were well
tolerated15.
Study protocol
Participants were studied in a randomised, double-
blind, cross-over fashion on three occasions each sepa-
rated by 3–7 days. Participants were provided with a
standardised meal (Beef lasagne, McCain Food, Wen-
douree, Victoria, Australia; energy content: 603 kcal), to
be consumed between 6.30 p.m. and 7 p.m. on the night
prior to each study. All participants were instructed to
maintain their normal eating habits between study days
and to discontinue their glucose-lowering medication for
48 h, and refrain from strenuous exercise and alcohol for
24 h, before each study. Participants were also asked to
abstain from any solids or liquids, except water (which
was allowed until 7 a.m.), after the evening meal until they
attended the Clinical Research Facility at the University of
Adelaide at 8.30 a.m. the next morning. An intravenous
cannula was placed into a forearm vein, and the arm was
kept warm with a heat pad for regular sampling of
‘arterialised’ blood. A baseline blood sample for mea-
surement of plasma glucose and hormones, and a baseline
antral area measurement, using two-dimensional (2D)
ultrasound, with the participant seated in an upright
position, were taken. Participants also completed a visual
analogue scale (VAS) questionnaire to assess gastro-
intestinal symptoms. Each participant was then intubated
with a soft-silicon feeding tube (outer diameter: 4 mm;
Dentsleeve, Mississauga, Ontario, Canada), which was
inserted through an anaesthetised nostril into the sto-
mach. Immediately thereafter (t=−31min, ~8.45 a.m.),
participants received the 200-mL intragastric bolus of one
of the two doses of tryptophan, or control, within 1 min.
The tube was then removed. Further blood samples and
VAS ratings were collected at t=−20, −10 and −1min.
At t=−1 min, each participant consumed, within 1 min,
a mixed-nutrient drink (350 mL, 500 kcal, 74 g
carbohydrates, including maltodextrin and sucrose, 18 g
protein and 15 g fat) consisting of 325-mL Nestle
Resource Plus® vanilla (Nestle Healthcare Nutrition,
Tongala, Victoria, Australia) plus 25-mL water to make
up the final volume, containing 3 g 3-OMG (Sigma-
Aldrich, Milwaukee, Wisconsin, USA). Blood samples and
VAS ratings were collected subsequently at 15-min
intervals from t= 15 to 60 min and at 30-min intervals
from t= 60 to 120 min. Measurements of antral area were
obtained immediately after the drink (t= 0min), at 5-min
intervals from t= 0 to 60 min, and at 15-min intervals
from t= 60 to 120min. At t= 120min, the cannula was
removed, and participants were provided with a light
lunch, after which they were free to leave the laboratory.
Measurements
Plasma glucose, C-peptide, glucagon and serum 3-OMG
concentrations
For glucose and hormones, venous blood samples
(7 mL) were collected into ice-chilled ethylenediaminete-
traacetic acid-containing tubes. For serum 3-OMG, 3-mL
venous samples were collected into untreated tubes and
allowed to clot. Plasma and serum were each separated by
centrifugation at 3200 rpm for 15min at 4 °C within
15min of collection and stored at −80 °C until sub-
sequent analysis.
Plasma glucose concentrations (mmol/L) were quanti-
fied by the glucose oxidase method using a glucose ana-
lyser (YSI 2300 Stat Plus, Yellow Springs Instruments,
Yellow Springs, Ohio, USA). Intra- and inter-assay coef-
ficient variations (CVs) were ≤2%.
Plasma C-peptide concentrations (pmol/L) were mea-
sured by ELISA immunoassay (10-1136-01, Mercodia,
Uppsala, Sweden). The minimum detectable limit was
15 pmol/L and the inter- and intra-assay CVs were 8.3%
and 2.9%, respectively. C-peptide reflects endogenous
insulin secretion, since it is not extracted by the liver and
its half-life is longer than that of insulin23.
Plasma glucagon concentrations (pg/mL) were mea-
sured by radioimmunoassay (GL-32K, Millipore, Billerica,
Massachusetts, USA). The minimum detectable limit was
15 pg/mL, and inter- and intra-assay CVs were 6.9% and
4.2%, respectively.
Serum 3-OMG concentrations (mmol/L) were mea-
sured by liquid chromatography and mass spectrometry,
with a sensitivity of 0.0103mmol/L24.
Gastric emptying
Gastric emptying was evaluated by measuring antral
area using 2D ultrasound (Aloka SSD-650 CL; ALOKA
Co. Ltd., Tokyo, Japan). Imaging was performed with the
transducer positioned vertically to obtain a sagittal image
of the antrum, with the superior mesenteric vein and the
abdominal aorta in a longitudinal section25. Images were
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taken at the end of inspiration to minimise the effects of
the motion of the stomach that occurs with regular
breathing26. A region-of-interest was drawn around the
cross-section of the antrum using in-built software. The
intragastric retention of the meal, expressed as a per-
centage of the meal at t= 0 min, at any given time25, and
the gastric half-emptying time (T50), defined as the time
taken for 50% of the meal to empty from the stomach27,
were calculated.
GI symptoms
Nausea and bloating were quantified using a VAS
questionnaire28. The strength of each sensation was rated
on a 100-mm horizontal line, where 0 mm represented
‘sensation not felt at all’ and 100mm ‘sensation felt the
greatest’. Participants were asked to indicate how they
were feeling at each time point by placing a vertical mark
on the 100-mm line.
Data and statistical analysis
The number of participants included was determined by
power calculations based on our previous studies15,16. We
calculated that n= 12 participants would allow detection
of a 1.0 mmol/L reduction in blood glucose at α= 0.05
with a power of 80%15.
Areas under the curve (AUCs) for plasma glucose, C-
peptide, glucagon and VAS ratings were calculated using
the trapezoidal rule, from t=−31 to −1min to assess the
effects of tryptophan alone, and from t=−1 to 120 min
(t= 0 to 120 min for gastric emptying and serum 3-OMG)
to assess the responses to the mixed-nutrient drink. AUCs
were analysed using general linear model mixed-model
analysis, with baseline values as a covariate. C-peptide and
glucagon concentrations at t=−1min (i.e. immediately
pre-drink), which we reported previously to correlate with
subsequent glycaemic control15, peak plasma glucose,
time to peak glucose and gastric half-emptying time (T50)
were analysed using repeated-measures analysis of var-
iance (ANOVA). Post-hoc comparisons, adjusted for
multiple comparisons by Bonferroni correction, using
parametric tests, were performed when significant
ANOVA effects were found. Statistical analysis was per-
formed using SPSS software (version 25, IBM, Chicago,
Illinois, USA). Differences were considered statistically
significant at P ≤ 0.05, and 0.05 < P ≤ 0.1 as trend. All data
are reported as mean ± SEM.
Results
All participants completed the study and tolerated the
study conditions well. There were no effects of treatment
on nausea or bloating, neither in response to tryptophan
alone nor after the mixed-nutrient drink (Table 1). No
participant had evidence of autonomic nerve dysfunction
(mean total score: 1.1 ± 0.1; range: 0–2).
Plasma glucose
Effect of tryptophan alone
There was no effect of treatment on fasting plasma
glucose.
Effect following the mixed-nutrient drink
There was a substantial rise in plasma glucose after the
drink on all days. While there was no effect of treatment
on overall plasma glucose AUC−1 to 120 min, there was a
treatment * time interaction for plasma glucose (P= 0.05).
Plasma glucose was lower after Trp-3 from t= 15–30 min
compared with control, and from t= 30–45min com-
pared with Trp-1.5 (P < 0.05 for all). There was no effect
of treatment on peak glucose concentration or the time to
peak concentration (Fig. 1 and Table 1).
Gastric emptying
There was an effect of treatment on gastric retention
AUC0 to 120 min (P= 0.04), which tended to be greater
after Trp-3 compared with control (P= 0.06). While there
was also an effect of treatment on T50 (P= 0.05), fol-
lowing post-hoc comparisons the difference between
treatments was not significant (Fig. 2 and Table 1).
Plasma C-peptide
Effect of tryptophan alone
There was an effect, albeit very small, of treatment on
fasting C-peptide AUC−31 to −1 min (P= 0.002), which
Fig. 1 Plasma glucose concentrations following intragastric
administration of 3 g (Trp-3) or 1.5 g (Trp-1.5) tryptophan, or
control, in participants with type 2 diabetes. After tryptophan
alone (i.e. t=−31 to −1 min), there was no effect on fasting plasma
glucose. Following the mixed-nutrient drink (i.e. t= 0 to 120min),
there was no effect on overall plasma glucose AUC−1 to 120 min.
However, there was a significant treatment * time interaction for
plasma glucose (P= 0.05); Plasma glucose after Trp-3 was lower from
t= 15 to 30 min compared with control (*P < 0.05), and from t= 30 to
45 min compared with Trp-1.5 (**P < 0.05). Data are expressed as
mean ± SEM; n= 12. Data were analysed using general linear model
mixed-model analysis, with baseline as covariate, and repeated-
measures ANOVA, and adjustments for multiple comparisons were
made using Bonferroni correction.
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tended to be greater after Trp-3 (P= 0.06), and was
greater after Trp-1.5 (P= 0.002), compared with control.
There was also an effect on C-peptide at t=−1min (P=
0.01), which was greater after both Trp-3 and Trp-1.5
compared with control (P < 0.05 for both).
Effect following the mixed-nutrient drink
C-peptide rose substantially after the drink on all days.
There was an effect of treatment on C-peptide AUC−1 to
120 min (P= 0.01), which tended to be greater after Trp-1.5
(P= 0.06), but not Trp-3, compared with control.
There was no treatment * time interaction (Fig. 3A and
Table 1).
Plasma glucagon
Effect of tryptophan alone
There was an effect of treatment on fasting glucagon
AUC−31 to −1min (P= 0.04), however, this was lost on
post-hoc comparisons. There was also an effect on glu-
cagon at t=−1 min (P= 0.007), which tended to be
greater after Trp-3 compared with control (P= 0.07).
Effect following the mixed-nutrient drink
There was a marked rise in plasma glucagon after the
drink on all days. However, there was no effect of treat-
ment on glucagon AUC−1 to 120 min, or a treatment * time
interaction (Fig. 3B and Table 1).
Fig. 2 Gastric emptying, expressed as % drink retention,
following intragastric administration of 3 g (Trp-3) or 1.5 g (Trp-
1.5) tryptophan, or control, in participants with type 2 diabetes.
There was an effect of treatment on gastric emptying AUC0 to 120 min
(P= 0.04), which tended to be greater after Trp-3 compared with
control (*P= 0.06). There was also an effect of treatment on T50 (P=
0.05), although this was lost on post-hoc comparisons. Data are
expressed as mean ± SEM; n= 12. Data were analysed using general
linear model mixed-model analysis, with baseline as covariate, and
adjustments for multiple comparisons made using Bonferroni
correction.
Fig. 3 Plasma C-peptide, B glucagon and C serum 3-OMG
concentrations following intragastric administration of 3 g
(Trp-3) or 1.5 g (Trp-1.5) tryptophan, or control, in participants
with type 2 diabetes. (A) After tryptophan alone (i.e. t=−31 to
−1min), there was an effect of treatment on C-peptide AUC−31 to
−1min (P=0.002), which tended to be greater after Trp-3 (
*P=0.06), and
was greater after Trp-1.5 (**P=0.002), compared with control. There
was also an effect on C-peptide at t=−1min (P=0.01), which was
greater after both Trp-3 and Trp-1.5 compared with control (*P<0.05
for both). Following the mixed-nutrient drink (i.e. t=0 to 120min),
there was an effect of treatment on C-peptide AUC−1 to 120min
(P=0.01), which tended to be greater after Trp-1.5, but not Trp-3
(***P=0.06). (B) After tryptophan alone, there was an effect of
treatment on fasting glucagon AUC−31 to −1min (P=0.04), however, this
was lost on post-hoc comparisons. There was also an effect on
glucagon at t=−1min (P=0.007), which tended to be greater after
Trp-3 compared with control (*P=0.07). Following the mixed-nutrient
drink, plasma glucagon rose on all days. However, there was no effect
of treatment on glucagon AUC−1 to 120min, or a treatment*time
interaction. (C) There was no effect of treatment on serum 3-OMG
AUC0 to 120min, or a treatment*time interaction. Data are expressed as
mean±SEM; n=12. Data were analysed using general linear model
mixed-model analysis, with baseline as covariate, and repeated-measures
ANOVA, adjusted for multiple comparisons using Bonferroni correction.
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Serum 3-OMG
There was no effect of treatment on serum 3-OMG
AUC0 to 120 min, or a treatment * time interaction (Fig. 3C
and Table 1).
Discussion
Our study indicates that in T2D, intragastric adminis-
tration of tryptophan, at a dose of 3 g, but not 1.5 g, delays
the rise in, but does not result in an overall lowering of,
the plasma glucose response to a carbohydrate-containing
mixed-nutrient drink, contrasting our previous observa-
tion in lean individuals or those with obesity15. Trypto-
phan slowed gastric emptying modestly, in line with our
recent findings in lean people and normoglycaemic people
with obesity15, which was likely responsible for delaying
the rise in postprandial plasma glucose. Tryptophan also
stimulated C-peptide, reflecting insulin secretion
(although this effect was very small), as well as glucagon;
the latter, therefore, most likely counteracted any glucose-
lowering effect of insulin.
Protein ‘preloads’ containing whey6 and oral adminis-
tration of specific amino acids29 have been shown to
diminish postprandial glycaemic excursions in T2D and,
accordingly, have the potential to be used in the man-
agement of T2D. We have reported that Trp-3, but not
Trp-1.5, modestly lowered blood glucose in response to a
mixed-nutrient drink in lean people and those with obe-
sity15. We, therefore, hypothesised that, in people with
T2D, in whom postprandial blood glucose is character-
istically elevated, the blood glucose-lowering effect of
tryptophan would be enhanced. Contrary to our hypoth-
esis, tryptophan did not diminish the overall postprandial
blood glucose, at either dose. However, Trp-3 modestly
reduced the initial glycaemic response to the drink, by
delaying the rise in blood glucose.
Gastric emptying is a major determinant of the gly-
caemic response to carbohydrate-containing meals in
health, obesity and T2D1, and our previous study showed
that Trp-3, administered intragastrically, slowed gastric
emptying in both lean people and those with obesity15.
Accordingly, the finding that tryptophan, in the same
dose, slowed gastric emptying in people with T2D is
consistent with these observations and is likely to account
for the delayed rise in blood glucose. It needs to be
recognised, though, that the magnitude of the slowing of
gastric emptying was modest, which may explain the lack
of effect on blood glucose lowering. The slowing of gastric
emptying after Trp-3 may explain the apparent lack of
effect of tryptophan on glucose absorption, as measured
by serum 3-OMG. That is, any effect of Trp-3 on glucose
absorption may have been masked by its effect to slow
gastric emptying. Because our study did not include
healthy participants as controls, the effect of tryptophan
on glucose absorption in health, and whether any effect of
tryptophan on glucose absorption may be altered in T2D,
remains unclear.
Trp-3 tended to stimulate, and Trp-1.5 had a small
effect to increase, plasma C-peptide immediately before
the nutrient drink. We have reported that intraduodenal
tryptophan, at a load of 0.15 kcal/min, providing ~3.3 g
over 90 min, had a small effect to stimulate insulin in
health16. This stimulation of insulin may reflect a direct
effect of circulating amino acids29 or be secondary to the
secretion of the incretin hormones, glucagon-like peptide-
1 (GLP-1) or glucose-dependent insulinotropic polypep-
tide (GIP), which both have glucose-dependent insulino-
tropic effects30,31. The insulin-stimulatory effect of GIP is
known to be markedly attenuated in T2D32. In healthy
participants, the small insulinotropic effect of tryptophan
is likely to be independent of GLP-1 and GIP16, as insulin
stimulation occurred at blood glucose levels of <8 mmol/
L33. After the drink, Trp-1.5, but not Trp-3, tended to
increase C-peptide compared with control; this may
reflect the lack of effect of Trp-1.5 to slow gastric emp-
tying. Nevertheless, overall the insulinotropic capacity of
tryptophan in the doses examined is modest. Therefore,
the absence of overall glucose lowering by tryptophan is
most likely due to only small insulin stimulation and
modest slowing of gastric emptying, combined with
relatively more potent stimulation of glucagon, possibly as
a direct response to circulating amino acids29. A pro-
gressive rise in glucagon for ~30min, followed by a sus-
tained elevation, was evident on all three days, consistent
with the well-established failure of postprandial glucagon
suppression characteristic of T2D34.
The potential mechanism(s) underlying the differences
in effects of tryptophan observed in this study, compared
with those in healthy people15, deserve some considera-
tion. Tryptophan may modulate GI motility, and, thus,
gastric emptying, locally via its metabolite, serotonin35, or
via CCK16,36. Tryptophan-induced stimulation of CCK
most likely involves Ca2+-sensing receptors (CaSR) on
enteroendocrine L cells37. Whether tryptophan-induced
stimulation of CCK is altered in T2D warrants evaluation
in future studies. The effect of tryptophan to stimulate
insulin may be directly at the pancreatic beta-cell via
activation of G protein-coupled receptor 142 (GPR142)
and/or CaSR38–40, and may also involve serotonin41. Since
people with T2D have beta-cell dysfunction, it is possible
that the effects of tryptophan on one or more of these
mechanisms may be attenuated, or the expression of these
receptors altered, in T2D42. This warrants further
investigation.
Some potential limitations of our study should be
appreciated. We deliberately studied patients with well-
controlled T2D (i.e. glycated haemoglobin is more
dependent on postprandial glucose) without autonomic
neuropathy and managed on oral hypoglycaemic drugs,
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but not insulin, as we considered that a glucose-lowering
effect of tryptophan would be most evident in this group.
It would be anticipated that in the cohort studied, the rate
of gastric emptying would be normal, or slightly acceler-
ated1. The two doses of tryptophan were based on our
previous studies; while it is tempting to speculate that
larger doses may have more potent effects, our previous
studies have indicated that these may be associated with
adverse effects16. Our study utilised intragastric adminis-
tration of tryptophan, however, administration in capsules
is also possible43, providing for a more practical applica-
tion outside the laboratory setting. We only included men
to avoid any effects of the menstrual cycle on gastric
emptying44, thus, extrapolation of our observations to
females should, of necessity, be circumspect.
In conclusion, our study suggests that in T2D, admin-
istration of tryptophan at a dose of 3 g before a
carbohydrate-containing drink delays the rise in plasma
glucose, probably as a result of slowing of gastric empty-
ing, but does not affect the overall blood glucose response.
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